NYU Cancer Health Disparity (CHD) SPORE

项目摘要 口腔消化道（ODT）癌症占美国癌症死亡的32%，表现出惊人的种族差异。 发病率和死亡率负担的差异。我们的中心假设是，人类微生物组有助于 通过微生物组与宿主在ODT肿瘤发生中的生物学相互作用，的 纽约大学癌症健康差异（CHD）SPORE的总体目标是开发一个全面的翻译 研究计划，以确定，了解和控制微生物，占口腔消化道（ODT） 癌症差异项目1将侧重于口腔微生物组与种族和社会经济的关系 通过一项前瞻性病例对照研究， 3个高度多样化的美国队列。项目2将侧重于肠道微生物组和黑人和白色种族 接受辅助化疗的结肠癌患者肿瘤复发的差异。我们的研究将 通过共享核心得到有力支持：（A）行政，（B）生物标本采购和利用，以及 (C)生物统计学和生物信息学。该提案汇集了一个高度跨学科的调查小组 在拟议研究的每个阶段协同工作，以实现以下转化目标： P20应用程序纽约大学CHD孢子将提供关于特定人类微生物群的新知识， 有助于ODT癌症的差异，并将促进我们对这些功能性后果的理解。 微生物群在ODT肿瘤发生中的作用。从P20 SPORE的拟议研究中获得的知识将 通过在少数人群中识别ODT癌症的高危人群来改变当前的临床实践， 为开发基于微生物的个性化预防和临床决策工具提供科学依据， 预防性干预，以解决ODT癌症的差异。P20 SPORE的实现将为 P50孢子的基础，以翻译这些基于证据的微生物因素的发现， 在诊所和社区层面，将ODT癌症差异纳入可操作的基于实践的干预措施。

PROJECT SUMMARY Orodigestive tract (ODT) cancers, which account for 32% of cancer deaths in the US, exhibit striking racial disparities in incidence and mortality burdens. Our central hypothesis is that the human microbiome contributes to ODT cancer disparities through biologic interaction of the microbiome with the host in ODT oncogenesis. The overall objective of the NYU Cancer Health Disparity (CHD) SPORE is to develop a comprehensive translational research program to identify, understand and control the microbiota that account for orodigestive track (ODT) cancer disparities. Project 1 will focus on the relationship of the oral microbiome to racial and socioeconomic disparities in the incidence of head and neck cancer, by means of a prospective case-control study nested within 3 large highly diverse US cohorts. Project 2 will focus on the gut microbiome and Black and White racial disparities in tumor recurrence in colon cancer patients who received adjuvant chemotherapy. Our research will be strongly supported through shared Cores: (A) Administrative, (B) Biospecimen Procurement & Utilization, and (C) Biostatistics and Bioinformatics. The proposal brings together a highly transdisciplinary team of investigators that work collaboratively through every stage of the proposed research to accomplish the translational goal of this P20 application. The NYU CHD SPORE will provide new knowledge on specific human microbiota that contribute to ODT cancer disparities and will advance our understanding of the functional consequences of these microbiota in ODT oncogenesis. The knowledge gained from the proposed research in the P20 SPORE will transform current clinical practice by identifying high risk groups for ODT cancer in minority populations, that will provide the scientific basis for developing microbially-based personalized prevention, clinical decision tools, and prophylactic interventions to address ODT cancer disparities. Achievement of the P20 SPORE will lay a solid groundwork for a P50 SPORE to translate these evidence-based findings of microbial factors contributing to ODT cancer disparity into actionable practice-based interventions at the clinic and community level.